FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309066381> ?p ?o ?g. }

• W4309066381 endingPage "116" @default.
• W4309066381 startingPage "103" @default.
• W4309066381 abstract "BACKGROUND: Acute myeloid leukemia (AML) is a significantly heterogeneous malignancy of the blood. Cytogenetic abnormalities are crucial for the prognosis of AML. However, since more than half of patients with AML are cytogenetically normal AML (CN-AML), predictive prognostic indicators need to be further refined. In recent years, gene abnormalities are considered to be strong prognostic factors of CN-AML, already having clinical significance for treatment. In addition, the relationship of methylation in some genes and AML prognosis predicting has been discovered. RASGEF1A is a guanine nucleotide exchange factors of Ras and widely expressed in brain tissue, bone marrow and 17 other tissues. RASGEF1A has been reported to be associated with a variety of malignant tumors, examples include Hirschsprung disease, renal cell carcinoma, breast cancer, diffuse large B cell lymphoma, intrahepatic cholangiocarcinoma and so on [1, 2]. However, the relationship between the RASGEF1A gene and CN-AML has not been reported. METHODS: By integrating the Cancer Genome Atlas (TCGA) database 75 patients with CN-AML and 240 Gene Expression Omnibus (GEO) database CN-AML samples, we examined the association between RASGEF1A’s RNA expression level and DNA methylation of and AML patients’ prognosis. Then, we investigated the RASGEF1A RNA expression and DNA methylation’s prognostic value in 77 patients with AML after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) as well as 101 AML patients after chemotherapy respectively. We investigated the association between sensitivity to Crenolanib and expression level of RASGED1A in patients by integrating 191 CN-AML patients from BeatAML dadataset. We integrated the expression and methylation of RASGEF1A to predict the CN-AML patients’ prognosis and investigated the relationship between prognostic of AML patients with different risk classification and expression levels or methylation levels of RASGEF1A. RESULTS: We found that RASGEF1A gene high expression group predicted poorer event-free survival (EFS) (P< 0.0001) as well as overall survival (OS) (P< 0.0001) in CN-AML samples, and the identical results were found in AML patients receiving chemotherapy (P< 0.0001) and Allo-HSCT (P< 0.0001). RASGEF1A RNA expression level is an CN-AML patients’ independent prognostic factor (EFS: HR = 5.5534, 95% CI: 1.2982–23.756, P= 0.0208; OS: HR = 5.3615, 95% CI: 1.1014–26.099, P= 0.0376). The IC50 (half maximal inhibitory concentration) of Crenolanib of CN-AML samples with RASGEF1A high expression level is lower. In addition, patients with high RASGEF1A methylation level had significant favorable prognosis (EPS: P< 0.0001, OS: P< 0.0001). Furthermore, the integrative analysis of expression and methylation of RASGEF1A could classify CN-AML patients into subgroups with different prognosis (EFS: P= 0.034, OS: P= 0.0024). Expression levels or methylation levels of RASGEF1A help to improve risk classification of 2010 European Leukemia Net. CONCLUSION: Higher RASGEF1A RNA expression and lower DNA methylation predicts CN-AML patients’ poorer prognosis. The RASGEF1A high expression level from patients with CN-AML have better sensitivity to Crenolanib. The integrative analysis of RASGEF1A RNA expression and DNA methylation can provide a more accurate classification for prognosis. Lower RASGEF1A expression is a favorable prognostic factor for AML patients receiving chemotherapy or Allo-HSCT. 2010 European Leukemia Net’s risk classification can be improved by RASGEF1A expression levels or methylation levels." @default.
• W4309066381 created "2022-11-21" @default.
• W4309066381 creator A5006962214 @default.
• W4309066381 creator A5023312754 @default.
• W4309066381 creator A5037677450 @default.
• W4309066381 creator A5048841778 @default.
• W4309066381 creator A5052289205 @default.
• W4309066381 creator A5054256274 @default.
• W4309066381 creator A5054546941 @default.
• W4309066381 creator A5054684639 @default.
• W4309066381 creator A5055770454 @default.
• W4309066381 creator A5062091853 @default.
• W4309066381 creator A5062682339 @default.
• W4309066381 creator A5066084730 @default.
• W4309066381 creator A5073571673 @default.
• W4309066381 creator A5076699095 @default.
• W4309066381 creator A5085933802 @default.
• W4309066381 date "2023-02-16" @default.
• W4309066381 modified "2023-10-05" @default.
• W4309066381 title "The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia" @default.
• W4309066381 cites W1255676896 @default.
• W4309066381 cites W1534965621 @default.
• W4309066381 cites W1567033121 @default.
• W4309066381 cites W1964451796 @default.
• W4309066381 cites W2003569144 @default.
• W4309066381 cites W2018205202 @default.
• W4309066381 cites W2019523681 @default.
• W4309066381 cites W2022335352 @default.
• W4309066381 cites W2027333481 @default.
• W4309066381 cites W2034058960 @default.
• W4309066381 cites W2036982851 @default.
• W4309066381 cites W2063107989 @default.
• W4309066381 cites W2070012795 @default.
• W4309066381 cites W2076025174 @default.
• W4309066381 cites W2101262547 @default.
• W4309066381 cites W2107398329 @default.
• W4309066381 cites W2112998845 @default.
• W4309066381 cites W2119574577 @default.
• W4309066381 cites W2130985642 @default.
• W4309066381 cites W2139077902 @default.
• W4309066381 cites W2139756825 @default.
• W4309066381 cites W2148047805 @default.
• W4309066381 cites W2152656267 @default.
• W4309066381 cites W2164864616 @default.
• W4309066381 cites W2167898988 @default.
• W4309066381 cites W2316323341 @default.
• W4309066381 cites W2412183643 @default.
• W4309066381 cites W2548532715 @default.
• W4309066381 cites W2556662769 @default.
• W4309066381 cites W2571053397 @default.
• W4309066381 cites W2725930552 @default.
• W4309066381 cites W2738123028 @default.
• W4309066381 cites W2792043667 @default.
• W4309066381 cites W2802026263 @default.
• W4309066381 cites W2896480326 @default.
• W4309066381 cites W2999104475 @default.
• W4309066381 cites W3087000282 @default.
• W4309066381 cites W3210991903 @default.
• W4309066381 cites W3217329167 @default.
• W4309066381 doi "https://doi.org/10.3233/cbm-210407" @default.
• W4309066381 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36404533" @default.
• W4309066381 hasPublicationYear "2023" @default.
• W4309066381 type Work @default.
• W4309066381 citedByCount "0" @default.
• W4309066381 crossrefType "journal-article" @default.
• W4309066381 hasAuthorship W4309066381A5006962214 @default.
• W4309066381 hasAuthorship W4309066381A5023312754 @default.
• W4309066381 hasAuthorship W4309066381A5037677450 @default.
• W4309066381 hasAuthorship W4309066381A5048841778 @default.
• W4309066381 hasAuthorship W4309066381A5052289205 @default.
• W4309066381 hasAuthorship W4309066381A5054256274 @default.
• W4309066381 hasAuthorship W4309066381A5054546941 @default.
• W4309066381 hasAuthorship W4309066381A5054684639 @default.
• W4309066381 hasAuthorship W4309066381A5055770454 @default.
• W4309066381 hasAuthorship W4309066381A5062091853 @default.
• W4309066381 hasAuthorship W4309066381A5062682339 @default.
• W4309066381 hasAuthorship W4309066381A5066084730 @default.
• W4309066381 hasAuthorship W4309066381A5073571673 @default.
• W4309066381 hasAuthorship W4309066381A5076699095 @default.
• W4309066381 hasAuthorship W4309066381A5085933802 @default.
• W4309066381 hasBestOaLocation W43090663812 @default.
• W4309066381 hasConcept C104317684 @default.
• W4309066381 hasConcept C121608353 @default.
• W4309066381 hasConcept C126322002 @default.
• W4309066381 hasConcept C143998085 @default.
• W4309066381 hasConcept C150194340 @default.
• W4309066381 hasConcept C190727270 @default.
• W4309066381 hasConcept C2778461978 @default.
• W4309066381 hasConcept C2778729363 @default.
• W4309066381 hasConcept C2779338263 @default.
• W4309066381 hasConcept C2779399171 @default.
• W4309066381 hasConcept C33288867 @default.
• W4309066381 hasConcept C502942594 @default.
• W4309066381 hasConcept C54355233 @default.
• W4309066381 hasConcept C71924100 @default.
• W4309066381 hasConcept C86803240 @default.
• W4309066381 hasConceptScore W4309066381C104317684 @default.
• W4309066381 hasConceptScore W4309066381C121608353 @default.

• next